Indivior director acquires 4,603 stock units in merger

Q: What equity awards did Bethany Sensenig receive in the INDV merger?

Bethany Sensenig's reported merger conversion included 4,603 restricted stock units and director stock options covering 37,198, 12,708, 11,236 and 7,665 shares. The options carried exercise prices of $19.63, $18.15, $21.77 and $32.60 per share, respectively.

The converted awards remain subject to substantially the same terms, with the restricted stock units settling in common stock upon vesting on February 18, 2027.

Available on EDGAR 11/04/2026 - 05:58 PM EST Accepted by SEC EDGAR 11/04/2026 - 05:58 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. (INDV) assumed Supernus Pharmaceuticals' outstanding equity awards in the merger effective November 2, 2026, converting them into corresponding awards of the renamed Supernus, Inc. Director Bethany Sensenig had 4,603 restricted stock units and four director stock-option awards recorded: 37,198, 12,708, 11,236 and 7,665 underlying shares, with exercise prices of $19.63, $18.15, $21.77 and $32.60 per share, respectively.

The converted awards remain subject to substantially the same terms and conditions, including vesting; prior award share counts were multiplied by the 1.5401 exchange ratio and rounded down, while per-share exercise prices were divided by that ratio and rounded up to the nearest whole cent. The restricted stock units settle in common stock upon vesting on February 18, 2027. The options expire on August 17, 2033, February 22, 2034, February 19, 2035 and February 18, 2036, respectively. Performance stock units were converted into time-vesting restricted stock units.

Insider Trade Summary

Other: 73,410 shares

Other 5 txns

Insider Sensenig Bethany

Role Director

Type	Security	Shares	Price	Value
Other	Restricted Stock Units ^{F1, F2}	4,603	$0.00	$0.00
Other	Director Stock Option (right to buy) ^F1	37,198	$0.00	$0.00
Other	Director Stock Option (right to buy) ^F1	12,708	$0.00	$0.00
Other	Director Stock Option (right to buy) ^F1	11,236	$0.00	$0.00
Other	Director Stock Option (right to buy) ^F1	7,665	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 4,603 contracts (Direct); Director Stock Option (right to buy) — 68,807 contracts (Direct)

Footnotes (2)

F1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.
F2. These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.

Key Figures

Restricted stock units: 4,603 restricted stock units Director stock options: 37,198 underlying shares; $19.63 exercise price per share Director stock options: 12,708 underlying shares; $18.15 exercise price per share +3 more

6 metrics

Restricted stock units 4,603 restricted stock units Settle in common stock upon vesting on February 18, 2027

Director stock options 37,198 underlying shares; $19.63 exercise price per share Expiration: August 17, 2033

Director stock options 12,708 underlying shares; $18.15 exercise price per share Expiration: February 22, 2034

Director stock options 11,236 underlying shares; $21.77 exercise price per share Expiration: February 19, 2035

Director stock options 7,665 underlying shares; $32.60 exercise price per share Expiration: February 18, 2036

Exchange ratio 1.5401 exchange ratio Prior award share counts were multiplied by this ratio

Key Terms

Restricted Stock Units, exchange ratio, vesting, time-vesting restricted stock units

4 terms

Restricted Stock Units financial

"These restricted stock units are settled in common stock upon vesting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exchange ratio financial

"multiplied by the 1.5401 exchange ratio"

The exchange ratio is the number used to decide how many shares of one company you get for each share you own in another company during a merger or acquisition. It’s like a recipe that tells you how to swap shares fairly, ensuring both companies’ values are balanced. This ratio matters because it determines how ownership divides between the companies' shareholders.

vesting financial

"subject to substantially the same terms and conditions, including vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

time-vesting restricted stock units financial

"converted into time-vesting restricted stock units"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Bethany Sensenig receive in the INDV merger?

Bethany Sensenig's reported merger conversion included 4,603 restricted stock units and director stock options covering 37,198, 12,708, 11,236 and 7,665 shares. The options carried exercise prices of $19.63, $18.15, $21.77 and $32.60 per share, respectively.

How were Supernus equity awards converted in the INDV merger?

Outstanding Supernus Pharmaceuticals equity awards were assumed by Indivior and converted into corresponding awards based on the 1.5401 exchange ratio, with resulting share counts rounded down. Exercise prices were divided by the ratio and rounded up to the nearest whole cent. Converted awards retained substantially the same terms, including vesting, except performance stock units became time-vesting restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sensenig Bethany

(Last)

(First)

(Middle)

C/O SUPERNUS, INC., 9715 KEY WEST AVENUE

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Supernus, Inc. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0.00	11/02/2026		J⁽¹⁾		4,603		02/18/2027⁽²⁾	⁽²⁾	Common Stock	4,603	$0.00	4,603	D
Director Stock Option (right to buy)	$19.63	11/02/2026		J⁽¹⁾		37,198		08/17/2024	08/17/2033	Common Stock	37,198	$0.00	37,198	D
Director Stock Option (right to buy)	$18.15	11/02/2026		J⁽¹⁾		12,708		02/22/2025	02/22/2034	Common Stock	12,708	$0.00	12,708	D
Director Stock Option (right to buy)	$21.77	11/02/2026		J⁽¹⁾		11,236		02/19/2026	02/19/2035	Common Stock	11,236	$0.00	11,236	D
Director Stock Option (right to buy)	$32.6	11/02/2026		J⁽¹⁾		7,665		02/18/2027	02/18/2036	Common Stock	7,665	$0.00	7,665	D

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except that performance stock unit awards were converted into time-vesting restricted stock units.

2. These restricted stock units are settled in common stock upon vesting, which occurs on February 18, 2027.

	/s/ Timothy C. Dec, as attorney-in-fact	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR